1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Celltrion’s Rituximab Biosimilar Heads To Panel Review With US FDA Backing, Thanks To Additional Clinical Trial

 
• By Sue Sutter

Non-inferiority study in advanced follicular lymphoma patients created uncertainty as to whether there were any clinically meaningful differences between CT-P10 and Genentech’s Rituxan, but a newly submitted, equivalence study appears to have put those concerns to rest for agency reviewers.  

Helping Hand_169455167_1200.jpg

Celltrion Inc.’s resubmitted biosimilar application for CT-P10 appears to have addressed the US FDA’s first-cycle review concerns as to whether there are any clinically meaningful differences between the proposed biosimilar and its reference product, Genentech Inc.’s Rituxan (rituximab).

In briefing documents released ahead of an Oct

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers